NCT05763563Completed
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy
Feasibility Of Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy
Source: ClinicalTrials.gov · Last updated 31 Mar 2026
Brief summary (registry, in English)
The purpose of the study is to evaluate an exercise program for individuals preparing for Chimeric Antigen Receptor (CAR) T-cell immunotherapy for hematological malignancies.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 28 Feb 2023
- Start date
- 21 Feb 2023
- Primary completion date
- 19 Jan 2025
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Diseases
- Multiple myeloma
- NCT number
- NCT05763563
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 21 Feb 2023 to the primary completion date, 19 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Screen failure for exercise safety based on Physical Activity Readiness Questionnaire (PAR-Q) and Patient-Reported Measurement Information System (PROMIS) screening questions
- Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV).
- Myopathic or rheumatologic disease that impacts physical function
- Cognitive, visual, or auditory limitations that preclude safe engagement in remotely-supervised resistance training sessions or independent aerobic exercise (as determined by patients' treating oncologists and specified in clinic notes outlining disease history).
Other
- Regular engagement in Resistance training (2x/week targeting all major muscle groups)
- Recent fracture or acute musculoskeletal injury that precludes ability to participate in RT using body weight
- Numeric pain rating scale of ≥ 7 out of 10
Who the study is looking for
- Age ≥65 years
- Lymphoma, leukemia, or myeloma with commercial FDA-approved CAR-T delivery planned for ≥4 weeks following enrollment
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Able to read and speak English fluently
- Capable of providing informed consent
- For optional, tele-supervised aerobic training procedure involving stationary bicycle delivery, participants must live within a 2-hour drive of Moffitt Cancer Center as determined via Google Maps.
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Moffitt Cancer Center Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.